Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust

BREAKING: Crude Oil Jumps 5% On Trump MoveModerna (MRNA) stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.The study's goal was to prevent cytomegalovirus from taking hold in study volunteers. CMV is a common virus and is generally harmless, but it can be a concern during pregnancy. A pregnant woman can pass the virus to the fetus, leading to congenital CMV. This can cause birth defects or long-term problems.Participants received shots at da ...